In the latest quarterly report ending September 2025, MYOMO demonstrated operational traction by surpassing revenue expectations even though net losses persisted. The company appointed William J. Febbo to its board in April 2026, bolstering strategic oversight with extensive medical device industry expertise. MYOMO’s business model centers on specialized mobility-enhancement devices with proprietary technology, maintaining competitive differentiation amid regulatory and market challenges. Financing through a $17.5 million committed term loan supports near-term development and commercialization initiatives but brings covenant constraints. Key risks remain around sustained losses and the pressure of ongoing innovation in a regulated environment.